Dr. Reddy's Laboratories Limited has informed the Exchange about Dividend Updates
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Reddy's announced audited consolidated results for Q4 and FY25 (year ended March 31, 2025). Q4FY25 revenue rose 20% year-on-year to Rs. 85,060 million, driven by the recently acquired Nicotine Replacement Therapy (NRT) business from Haleon and growth in Global Generics. Full-year revenue grew 17% to Rs. 325,535 million, but profit after tax attributable to shareholders rose only 2% to Rs. 56,544 million due to higher costs and impairments. Q4 profit after tax jumped 22% year-on-year to Rs. 15,939 million. The board recommended a final dividend of Rs. 8 per equity share (face value Rs. 1) and re-appointed G V Prasad as Co-Chairman & Managing Director for five years from January 2026. Statutory auditors issued an 'Unmodified Opinion' (clean audit) on the financials.
Strong Q4 revenue growth and clean audit opinion are positives for shareholders, but muted full-year PAT growth (just 2%) and gross margin compression (down 300 bps YoY in Q4) suggest margin pressures from price erosion and acquisition costs. The Rs. 8 dividend continues the company's regular payout, and the NRT acquisition is meaningfully boosting top-line growth in Europe.